益生菌或可改善结直肠癌患者的术后指标
创作:szx 审核:szx 2019年12月30日
  • 纳入21项RCT(涉及1831名接受了手术治疗的结直肠癌患者)进行系统性回顾,分析益生菌对患者术后各项指标的影响;
  • 共涉及23个益生菌菌种,最常用的是嗜酸乳杆菌及长双歧杆菌,9项研究使用了多菌株益生菌组合;
  • 益生菌可显著减少患者术后的炎症因子水平、化疗副作用、严重腹泻、术后感染并发症及接受抗生素治疗的持续时间;
  • 同时,益生菌显著增加了患者粪便菌群中的放线菌门,并改变了肿瘤组织中的菌群组成。
主编推荐语
szx
Clinical Nutrition上发表的一项最新研究,对2007-2017年间的相关研究进行了系统性回顾,发现在接受手术治疗的结直肠癌患者中,术前使用益生菌或能显著改善患者术后的多项指标。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Clinical Nutrition [IF:6.402]

The effects of probiotics on reducing the colorectal cancer surgery complications: A periodic review during 2007–2017

益生菌对减少结直肠癌手术并发症的效果:对2007-2017年间研究的综述

10.1016/j.clnu.2019.11.008

2019-12-09, Article

Abstract & Authors:展开

Abstract:收起
Background & aims: To assess the effects of pro-/synbiotic treatment on patients with colorectal cancer (CRC), a systematic review was conducted on randomized controlled trials.
Methods: International databanks (ISI Web of Science, PubMed, Scopus, and Google Scholar) were searched from January 2007 to December 2017 using the following keywords: ‘colorectal cancer’ and ‘probiotics’. The search was restricted to original articles published in English. Reference lists of all related studies were also reviewed to find other relevant publications. The statistical analysis was performed using SPSS software version 18.0 (IBM, NY, USA). Also, p < .05 was regarded as statistically significant.
Results: A total of 21 clinical trials were retrieved, involving 1831 patients subjected to elective colorectal surgery. The studies included in this review have investigated the effects of probiotics on different aspects of colorectal cancer treatment (p < .05). According to the present study results, probiotics could significantly decrease inflammatory factors, chemotherapy side effects, severe diarrhea, postoperative infectious complications, and duration of antibiotic therapy; shift fecal microbiota in favor of Actinobacteria; and change the tumor tissue microbiota (p < .05).
Conclusion: Based on the present review, the preoperative use of pro-/synbiotics as prophylaxis for patients with CRC could improve clinical outcomes. More detailed data about the types of probiotic species and the optimal consumption dose of pro-/synbiotics should be taken in to account in future meta-analysis reviews.

First Authors:
Atieh Darbandi

Correspondence Authors:
Malihe Talebi

All Authors:
Atieh Darbandi,Maryam Mirshekar,Aref Shariati,Majid Taati Moghadam,Vahid Lohrasbi,Parisa Asadolahi,Malihe Talebi

评论